Vol. 11 (06) pp. 1263-1265 DOI: 10.21474/IJAR01/17188

PROSTATE CANCER SCREENING USING THE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST

12 Downloads 56 Views
Crossref

Download Full Paper (PDF)

Abstract

We aimed to conduct a systematic review and meta-analysis on published literature extracted from PubMed/Medline, Google scholar, and Cochrane library. The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, over diagnosis, and costs.

Article Analytics

How to Cite This Article

Rahim Abbas (2023); PROSTATE CANCER SCREENING USING THE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST, Int. J. of Adv. Res., 11 (06), 1263-1265, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/17188

Corresponding Author

RAHIM ABBAS

India
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.